Talking Medicines targets messaging risk in pharma brand strategy

Tern plc

Pharma teams typically begin with a clear brand narrative built on scientific evidence. But as this narrative moves through marketing, compliance and external agencies, the original message can become diluted. When that happens, healthcare professionals may misinterpret or disengage from the brand. The result is weaker positioning, lower impact and reduced return on marketing investment.

Talking Medicines addresses this problem by offering real-time analytics that measure how healthcare professionals actually receive and interpret brand messages. Instead of waiting for post-campaign reports, teams can see early signals of what is working and adjust strategy before value is lost. This is especially relevant during launch phases, where the ability to course-correct quickly can have a material impact on performance.

Its DrugVoice platform captures unstructured HCP dialogue and turns it into structured insight. This data helps brand teams understand whether their messages are understood, aligned with clinical priorities and prompting the right actions. For leadership, it offers a way to verify that brand strategy is being delivered as intended.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Fundamental XR expands access to immersive training with web-enabled platform

Its new Immersive Web platform brings immersive training into the browser, lowering adoption barriers and broadening enterprise reach.

GLP-1 receptor agonists: Strategic market shift

Rapid uptake, evolving regulation and digital integration are reshaping the investment case for metabolic health therapies.

The Cyber Resilience Act forces a security reset for connected device makers

Device Authority helps manufacturers operationalise Cyber Resilience Act compliance through automated device identity and secure update management.

Pharmaceutical groups move closer to the consumer in strategic marketing reset

Pharmaceutical marketing is shifting towards direct consumer engagement, reshaping how companies compete and manage risk in a digital environment.

Changing clinician behaviour reshapes commercial strategy for 2026

As clinician engagement becomes more digital and measurable, companies that act on behavioural data can improve targeting, reduce risk and strengthen competitive positioning in 2026.

Tern Plc launches £384,408 Open Offer at 0.40p per share

Tern Plc has announced an Open Offer to raise up to £384,408 through the issue of up to 96,101,957 shares at 0.40p each, a 20% discount to the 12 February 2026 closing price.

Search

Search